Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

X4 Pharmaceuticals Q3 EPS $(0.01) Beats $(0.15) Estimate. Cash and Equivalents $142.7M

Author: Benzinga Newsdesk | November 09, 2023 07:10am
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.15) by 93.33 percent. This is a 96.15 percent increase over losses of $(0.26) per share from the same period last year.

Posted In: XFOR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist